Latest Product Launches News

The Calmer Co. has pushed back the closing date of its $3.5 million renounceable entitlement offer to give shareholders more time to participate, including those overseas.

Resmed delivered a strong FY2026 with 10% revenue growth to $5.7 billion, a 17% rise in non-GAAP EPS, and a 10% dividend hike. Strategic moves include selling MatrixCare and acquiring Noctrix Health.

Galan Lithium is set to become a significant lithium brine producer with its Hombre Muerto West project in Argentina, targeting first sales in the second half of 2026. The company boasts a world-class resource, strong fiscal incentives, and a valuation discount to ASX peers.

AoFrio’s revenue fell 21.5% in 1H26, dragged down by a 50.5% plunge in motor sales due to US tariffs, while IoT revenue grew modestly. The company launched new cellular and software platforms, raised NZD 8.9 million, and is expanding into Food Retail, but full-year revenue growth now looks unlikely.

Atomos Limited has turned a corner in FY26, posting over 20% sales growth to around $40 million and swinging to EBITDA profitability after prior losses, boosted by new product launches and the strategic acquisition of Flanders Scientific.

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.

The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.

Peak Processing (ASX: PKP) has recorded its first positive Group EBITDA quarter, driven by record beverage production and a significant US manufacturing agreement, marking a pivotal turnaround in FY26.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

Nodestream has advanced its defence strategy with key leadership hires, a $6.5 million capital raise, and fresh product launches, while expanding its footprint in the US and European markets.

Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.

Microba Life Sciences has wrapped up a $5.41 million capital raise combining a $5 million institutional Placement and a $407,500 Share Purchase Plan, strengthening its balance sheet to accelerate growth in Australia and the UK.